Table 1 Demographic and clinical characteristics before and during the COVID-19 Pandemic (n = 547)
Variable | Total | Pre-COVID-19 Era (2016–2019) | COVID-19 Era (2020–2022) | P-value |
|---|---|---|---|---|
n (%) 547 (100.0) | n (%) 190 (34.8) | n (%) 357 (65.2) | ||
Age (years) | ||||
00–04 | 195 (35.6) | 67 (35.3) | 128 (35.9) |  |
05–09 | 128 (23.4) | 36 (18.9) | 92 (25.8) | 0.022 |
10–14 | 109 (19.9) | 34 (17.9) | 75 (21.0) |  |
15–19 | 115 (21.0) | 53 (27.9) | 62 (17.4) |  |
Sex | ||||
Male | 319 (58.3) | 109 (57.4) | 210 (58.3) | Â |
Female | 228 (41.7) | 81 (42.6) | 147 (41.7) | 0.742 |
Region | ||||
Kilimanjaro | 208 (38.0) | 78 (40.8) | 130 (36.4) | Â |
Other | 339 (62.0) | 112 (58.6) | 227 (63.6) | 0.287 |
Time travel | ||||
Less than 1Â h | 141 (25.8) | 55 (29.0) | 86 (24.0) | Â |
Between 2–5 h | 338 (61.8) | 114 (60.0) | 224 (62.8) | 0.421 |
More than 6Â h | 68 (12.4) | 21 (11.0) | 47 (13.2) | Â |
Treatment | ||||
Radiotherapy | ||||
No | 507 (92.7) | 177 (93.2) | 330 (92.4) | Â |
Yes | 40 (7.3) | 13 (6.8) | 27 (7.6) | 0.758 |
Chemotherapy | ||||
No | 103 (18.8) | 28 (14.7) | 75 (21.0) | Â |
Yes | 444 (81.2) | 162 (85.3) | 282 (79.0) | 0.074 |
Surgery | ||||
No | 407 (74.4) | 160 (84.2) | 247 (69.2) | Â |
Yes | 140 (25.6) | 30 (15.8) | 110 (30.8) | < 0.001 |
Diagnosis | ||||
Group I | 126 (23.0) | 38 (20.0) | 88 (26.4) | Â |
Group II | 122 (22.3) | 42 (22.1) | 80 (22.4) | Â |
Group III | 26 (4.8) | 8 (4.2) | 18 (5.0) | Â |
Group IV | 8 (1.5) | 3 (1.6) | 5 (1.4) | Â |
Group V | 80 (14.6) | 24 (12.6) | 56 (15.7) | 0.793 |
Group VI | 72 (13.2) | 30 (15.8) | 42 (11.8) | Â |
Group VII | 7 (1.3) | 2 (1.1) | 5 (1.4) | Â |
Group VIII | 30 (5.5) | 13 (6.8) | 17 (4.8) | Â |
Group IX | 45 (8.2) | 17 (8.9) | 28 (7.8) | Â |
Group X | 8 (1.5) | 4 (2.1) | 4 (1.1) | Â |
Group XI | 15 (2.7) | 7 (3.7) | 8 (2.2) | Â |
Group XII | 1.5 (8) | 2 (1.1) | 6 (1.7) | Â |
Date of last contact | ||||
Alive | 436 (79.7) | 150 (81.1) | 286 (80.1) | Â |
Dead | 106 (19.4) | 35 (18.9) | 71 (19.9) | 0.008 |
Unknown | 5 | 5 | 0 | Â |